Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Jennifer M. Connelly MD

Jennifer M. Connelly MD profile photo picture

Associate Professor

Institution: Medical College of Wisconsin
Department: Neurology
Division: General
Program: Neuro-Oncology

Member of the Cancer Center


Clinical Expertise

  • Brain Neoplasms
  • Brain Stem Neoplasms
  • Diffusion Magnetic Resonance Imaging
  • Glioblastoma
  • Glioma
  • Hamartoma Syndrome, Multiple
  • Li-Fraumeni Syndrome
  • Neurofibromatosis 1
  • Neurofibromatosis 2
  • Tuberous Sclerosis
  • Leadership Positions

  • Co-Director of the Neuro-Oncology Program
  • Publications (22)

  • NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. (Lee EQ, Zhang P, Wen PY, Gerstner ER, Reardon DA, Aldape KD, deGroot JF, Pan E, Raizer JJ, Kim LJ, Chmura SJ, Robins HI, Connelly JM, Battiste JD, Villano JL, Wagle N, Merrell RT, Wendland MM, Mehta MP) Cancer 2020 06 15;126(12):2821-2828 PMID: 32154928 PMCID: PMC7245544 SCOPUS ID: 2-s2.0-85081276146 03/11/2020    
  • Longitudinal molecular trajectories of diffuse glioma in adults. (Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW, GLASS Consortium) Nature 2019 12;576(7785):112-120 PMID: 31748746 PMCID: PMC6897368 SCOPUS ID: 2-s2.0-85075234677 11/22/2019       23 Citations
  • High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature. (Kapke JT, Schneidewend RJ, Jawa ZA, Huang CC, Connelly JM, Chitambar CR) Hematol Oncol Stem Cell Ther 2019 Dec;12(4):189-193 PMID: 31629723 SCOPUS ID: 2-s2.0-85075443191 10/21/2019       1 Citation
  • Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors. (Schmainda KM, Prah MA, Hu LS, Quarles CC, Semmineh N, Rand SD, Connelly JM, Anderies B, Zhou Y, Liu Y, Logan B, Stokes A, Baird G, Boxerman JL) AJNR Am J Neuroradiol 2019 04;40(4):626-633 PMID: 30923088 PMCID: PMC6461489 SCOPUS ID: 2-s2.0-85064588009 03/30/2019       7 Citations
  • Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. (Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, Chitambar CR, Clark P, Kuo J, Schmainda KM, Mirza SP) Oncotarget 2017 Dec 22;8(68):112662-112674 PMID: 29348854 PMCID: PMC5762539 01/20/2018    
  • Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics. (Prah MA, Al-Gizawiy MM, Mueller WM, Cochran EJ, Hoffmann RG, Connelly JM, Schmainda KM) J Neurooncol 2018 Jan;136(1):13-21 PMID: 28900832 PMCID: PMC5756123 SCOPUS ID: 2-s2.0-85029185195 09/14/2017       11 Citations
  • Acid ceramidase confers radioresistance to glioblastoma cells. (Doan NB, Nguyen HS, Al-Gizawiy MM, Mueller WM, Sabbadini RA, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP) Oncol Rep 2017 Oct;38(4):1932-1940 PMID: 28765947 PMCID: PMC5652937 SCOPUS ID: 2-s2.0-85029804998 08/03/2017       16 Citations
  • Acid ceramidase is a novel drug target for pediatric brain tumors. (Doan NB, Nguyen HS, Montoure A, Al-Gizawiy MM, Mueller WM, Kurpad S, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP) Oncotarget 2017 Apr 11;8(15):24753-24761 PMID: 28445970 PMCID: PMC5421885 SCOPUS ID: 2-s2.0-85017541087 04/28/2017    
  • Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. (Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N) BMC Cancer 2016 11 04;16(1):842 PMID: 27809808 PMCID: PMC5096303 SCOPUS ID: 2-s2.0-84994355377 11/05/2016       6 Citations
  • A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. (Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, Damek D, Bota DA, Connelly J) CNS Oncol 2017 01;6(1):29-43 PMID: 27628854 PMCID: PMC6027938 SCOPUS ID: 2-s2.0-85050579311 09/16/2016       12 Citations
  • Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. (Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS) AJNR Am J Neuroradiol 2016 Dec;37(12):2201-2208 PMID: 27492073 PMCID: PMC5161572 SCOPUS ID: 2-s2.0-85006469905 08/06/2016       24 Citations
  • Location of brain tumor intersecting white matter tracts predicts patient prognosis. (Mickevicius NJ, Carle AB, Bluemel T, Santarriaga S, Schloemer F, Shumate D, Connelly J, Schmainda KM, LaViolette PS) J Neurooncol 2015 Nov;125(2):393-400 PMID: 26376654 PMCID: PMC6094943 SCOPUS ID: 2-s2.0-84945477926 09/18/2015       7 Citations
  • Photodynamic therapy (PDT) for malignant brain tumors--where do we stand? (Quirk BJ, Brandal G, Donlon S, Vera JC, Mang TS, Foy AB, Lew SM, Girotti AW, Jogal S, LaViolette PS, Connelly JM, Whelan HT) Photodiagnosis Photodyn Ther 2015 Sep;12(3):530-44 PMID: 25960361 SCOPUS ID: 2-s2.0-84940900716 05/12/2015       96 Citations
  • Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. (LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi JA, Malkin MG, Mueller WM, Schmainda KM) Neuro Oncol 2014 Dec;16(12):1599-606 PMID: 25059209 PMCID: PMC4232087 SCOPUS ID: 2-s2.0-84938693563 07/26/2014       34 Citations
  • Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics. (Heroux MS, Chesnik MA, Halligan BD, Al-Gizawiy M, Connelly JM, Mueller WM, Rand SD, Cochran EJ, LaViolette PS, Malkin MG, Schmainda KM, Mirza SP) Physiol Genomics 2014 Jul 01;46(13):467-81 PMID: 24803679 PMCID: PMC4587597 SCOPUS ID: 2-s2.0-84903603535 05/08/2014       24 Citations
  • Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. (Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG) Neuro Oncol 2014 Jun;16(6):880-8 PMID: 24431219 PMCID: PMC4022214 SCOPUS ID: 2-s2.0-84901024226 01/17/2014       72 Citations
  • Effects of perfusion on diffusion changes in human brain tumors. (Cohen AD, LaViolette PS, Prah M, Connelly J, Malkin MG, Rand SD, Mueller WM, Schmainda KM) J Magn Reson Imaging 2013 Oct;38(4):868-75 PMID: 23389889 PMCID: PMC3735792 SCOPUS ID: 2-s2.0-84886901290 02/08/2013       5 Citations
  • Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. (LaViolette PS, Cohen AD, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM) Neuro Oncol 2013 Apr;15(4):442-50 PMID: 23382287 PMCID: PMC3607265 SCOPUS ID: 2-s2.0-84875717479 02/06/2013       36 Citations
  • Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. (Ellingson BM, LaViolette PS, Rand SD, Malkin MG, Connelly JM, Mueller WM, Prost RW, Schmainda KM) Magn Reson Med 2011 Apr;65(4):1131-43 PMID: 21413079 PMCID: PMC3065939 SCOPUS ID: 2-s2.0-79952781642 03/18/2011       36 Citations
  • Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. (Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM) J Neurooncol 2011 Mar;102(1):95-103 PMID: 20798977 PMCID: PMC3033973 SCOPUS ID: 2-s2.0-79952194217 08/28/2010       51 Citations
  • Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. (Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, Schmainda KM) J Magn Reson Imaging 2010 Mar;31(3):538-48 PMID: 20187195 PMCID: PMC2903058 SCOPUS ID: 2-s2.0-77649224700 02/27/2010       157 Citations
  • Environmental risk factors for brain tumors. (Connelly JM, Malkin MG) Curr Neurol Neurosci Rep 2007 May;7(3):208-14 PMID: 17488586 SCOPUS ID: 2-s2.0-34249717736 05/10/2007       54 Citations
  • Last update: 05/11/2020
    jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a